Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Fevzi, Altuntas"'
Autor:
Samet Yaman, Semih Basci, Gökhan Turan, Bahar Uncu Ulu, Tugçe Nur Yigenoglu, Taha Bahsi, Haktan Bagis Erdem, Mehmet Sinan Dal, Merih Kizil Çakar, Fevzi Altuntas
Publikováno v:
Iraqi Journal of Hematology, Vol 11, Iss 2, Pp 130-133 (2022)
BACKGROUND: Polycythemia is a common reason for patients' admissions. With the introduction of COVID-19, face masks reached very common usage in the population. Masks may cause some degree of hypoxia that may result in high hemoglobin in healthy indi
Externí odkaz:
https://doaj.org/article/044163731e0a4e45ad3c0d24ad6691b4
Autor:
Nurgul Ozcan, Semih Basci, Eda Ozcan, Mehmet Bakirtas, Mehmet Sinan Dal, Merih Kizil Cakar, Fatma Meric Yilmaz, Fevzi Altuntas
Publikováno v:
Medicine Science, Vol 10, Iss 2, Pp 455-61 (2021)
Plasma cell leukemia (PCL) is a rare (1-2 %) aggressive plasma cell dyscrasia (PCD) with a poor prognosis and characterized by the presence of more than 20% circulating plasma cells (PCs). Multicolor Flowcytometry is used for differentiating PCs in P
Externí odkaz:
https://doaj.org/article/3671ec5b6a604de282779e3d5dfa668b
Autor:
Mehmet Bakirtas, Tugce Nur Yigenoglu, Semih Basci, Bahar Uncu Ulu, Nurgul Ozcan, Merih Kizil Cakar, Mehmet Sinan Dal, Fevzi Altuntas
Publikováno v:
Sanamed, Vol 15, Iss 1, Pp 15-19 (2020)
Introduction: Despite multiple lines of chemotherapy, some patients with acute myeloid leukemia (AML) can not achieve remission. The prognosis of these patients is quite poor and they should be evaluated for clinical trials, otherwise myeloablative c
Externí odkaz:
https://doaj.org/article/67540c6b7df64799861776b155948a55
Autor:
Mehmet Bakırtaş, Mehmet Sinan Dal, Tuğçe Nur Yiğenoğlu, Asli Odabası Giden, Istemi Serin, Semih Başcı, Yasin Kalpakci, Serdal Korkmaz, Omer Ekinci, Murat Albayrak, Abdulkadir Basturk, Duzgun Ozatli, Mehmet Hilmi Dogu, Tuba Hacıbekiroglu, Merih Kızıl Çakar, Turgay Ulas, Mine Miskioglu, Emine Gulturk, Bulent Eser, Fevzi Altuntas
Publikováno v:
Journal of Chemotherapy. :1-7
Publikováno v:
Acta Oncologica Turcica. 55:72-76
Autor:
Duzgun Ozatli, Aslı Odabaşı Giden, Mehmet Ali Erkurt, Serdal Korkmaz, Semih Basci, Turgay Ulas, Burhan Turgut, Tugce Nur Yigenoglu, Tuba Hacibekiroglu, Abdulkadir Basturk, Mehmet Sinan Dal, Sinem Namdaroglu, Fehmi Hindilerden, Sibel Kabukcu Hacioglu, Gulsum Akgun Cagliyan, Gul Ilhan, Murat Kacmaz, Ayşe Uysal, Mustafa Merter, Omer Ekinci, Fadime Ersoy Dursun, Atakan Tekinalp, Sinan Demircioglu, Gulden Sincan, Didar Yanardag Acik, Aydan Akdeniz, Mehmet Ali Ucar, Mahmut Yeral, Rafiye Ciftciler, Hava Uskudar Teke, Elif Gulsum Umit, Abdullah Karakus, Yusuf Bilen, Osman Yokus, Murat Albayrak, Cengiz Demir, Vahap Okan, Songül Serefhanoglu, Sami Kartı, Zubeyde Nur Ozkurt, Bulent Eser, Ismet Aydogdu, Irfan Kuku, Seckin Cagirgan, Mehmet Sonmez, Gulsum Ozet, Fevzi Altuntas
Publikováno v:
Transfusion and Apheresis Science. 62:103662
Autor:
Dicle İskender, Seval Yılmaz-Ergani, Munevver Aksoy, Betul Tokgoz, Mujde Can Ibanoglu, Merih Kızıl Çakar, Turhan Caglar, Fevzi Altuntas
Publikováno v:
Cureus
Background Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm characterized by persistently elevated platelet count without a clear secondary cause. Although most patients with ET are between 55 and 60 years of age, it has been e
Autor:
Sema, Secilmis, Mehmet, Sinan Dal, Merih, Kizil Cakar, Alparslan, Merdin, Nuran, Ahu Baysal, Fevzi, Altuntas
Publikováno v:
Journal of B.U.ON. : official journal of the Balkan Union of Oncology. 26(5)
Venetoclax (VEN) is an oral selective inhibitor of antiapoptotic protein B-cell leukemia/lymphoma-2 (BCL-2).We report 7 relapsed/refractory (R/R) acute myeloid leukemia (AML) patients treated with venetoclax and hypomethylating agents (HMA).More than
Autor:
Mehmet, Sinan Dal, Alparslan, Merdin, Mehmet Ali, Erkurt, Ömer, Ekinci, Murat, Albayrak, Sibel, Kabukcu Hacıoglu, Ayse, Kaya, Mehmet Hilmi, Dogu, Fehmi, Hindilerden, Ahmet, Sarici, Mustafa, Merter, Merih, Reis Aras, Gulsum, Akgun Caglıyan, Merih, Kizil Cakar, Ismet, Aydogdu, Irfan, Kuku, Serdal, Korkmaz, Turgay, Ulas, Bulent, Eser, Fevzi, Altuntas
Publikováno v:
Journal of B.U.ON. : official journal of the Balkan Union of Oncology. 26(4)
Pralatrexate is a new generation antifolate treatment agent used for the treatment of relapsed or refractory peripheral T-cell lymphomas. This study aims to determine the general characteristics of the patients receiving pralatrexate therapy in Turke
Autor:
null Olga Meltem Akay, null Murat Ozbalak, null Mustafa Pehlivan, null Birol Yildiz, null Ant Uzay, null Tugce Nur Yigenoglu, null Tugrul Elverdi, null Leylagul Kaynar, null Orhan Ayyildiz, null Ipek Yonal Hindilerden, null Hasan Sami Goksoy, null Sebnem Izmir Guner, null Ahmet Kursad Gunes, null Mehmet Sonmez, null Meltem Kurt Yuksel, null Sinem Civriz Bozdag, null Zubeyde Nur Ozkurt, null Tayfur Toptas, null Mehmet Hilmi Dogu, null Ozan Salim, null Guray Saydam, null Irfan Yavasoglu, null Meltem Ayli, null Gulsum Ozet, null Murat Albayrak, null Elif Birtas Atesoglu, null Selami K. Toprak, null Rahsan Yildirim, null Ozgur Mehtap, null Sevgi Kalayoglu Besisik, null Meliha Nalcaci, null Fevzi Altuntas, null Burhan Ferhanoglu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a169dfe3149b0b8d46caf5c1faf24b5a
https://doi.org/10.1002/hon.2897/v2/response1
https://doi.org/10.1002/hon.2897/v2/response1